The goals of the Cancer Cell and Gene Therapy (CCGT) Program are to incorporate advances in cellular and gene therapy into the treatment of cancer. The Cancer Center Program is a sub-component of the Center for Cell and Gene Therapy and has 18 research members from a multiple Departments at Baylor, including Medicine, Pediatrics, Pathology, Immunology and Molecular and Human Genetics. The program had a total of $6,315,268 support from the NCI last year and overall received $18,522,146 in peer reviewed funding. Members of the program published over 180 cancer related manuscripts in peer-reviewed journals of which 51% represented intraprogrammatic collaborations and 30% interprogrammatic. Our research focuses on normal and malignant stem cells, adoptive immunotherapy of cancer and on improving outcomes of stem cell transplantation for cancer. CCGT has basic, translational and clinical research components. Our basic investigators work on understanding the mechanisms by which normal and malignant stem cell growth is controlled, and on the molecular and cellular interactions involved in development of tumor vasculature and stroma. These researchers are also identifying new targets for immunotherapy, and optimizing presentation of weak tumor antigens to the immune system. Our translational investigators are moving cell and gene based therapies from the bench to the bedside in a series of small-scale iterative laboratory-clinical- laboratory protocols, and are also developing pivotal trials. We have a decade-long history of successful and timely implementation of clinical translational projects in gene and cellular therapy, and we have the resources to supply and test all the clinical reagents required, since our center is one of three national NHLBl-funded Production Assistance for Cellular Therapy centers. Major accomplishments include the demonstration of activity of virus specific cytotoxic T lymphocytes in virus-associated cancers (resulting in an orphan drug designation for EBV CTLs for post transplant lymphoma) and studies showing the antitumor activity of genetically modified T cells in subjects with neuroblastoma and lymphoma. Our clinical researchers run the adult and (in collaboration with the Pediatric Oncology program) pediatric hemopoietic stem cell transplant programs and are extending the applicability of transplantation for malignancy by using monoclonal antibodies in subablative conditioning regimens and using post transplant immunotherapy to reduce GVHD whilst augmenting graft versus tumor activity and reconstituting anti-viral immunity.

Public Health Relevance

This program consists of basic scientists and clinicians who focus their research efforts on stem cell biology and cancer stem cells, adoptive immunotherapy of cancer and improving the outcome of stem cell transplantation for cancer. Their collaborations have led to studies showing activity of the immune system in treating cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA125123-04
Application #
8181352
Study Section
Subcommittee G - Education (NCI)
Project Start
2010-09-17
Project End
2015-06-30
Budget Start
2010-09-17
Budget End
2011-06-30
Support Year
4
Fiscal Year
2010
Total Cost
$17,826
Indirect Cost
Name
Baylor College of Medicine
Department
Type
DUNS #
051113330
City
Houston
State
TX
Country
United States
Zip Code
77030
Creighton, Chad J (2018) The clinical applications of The Cancer Genome Atlas project for bladder cancer. Expert Rev Anticancer Ther 18:973-980
Guarducci, Cristina; Bonechi, Martina; Benelli, Matteo et al. (2018) Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer. NPJ Breast Cancer 4:38
Byrd, Tiara T; Fousek, Kristen; Pignata, Antonella et al. (2018) TEM8/ANTXR1-Specific CAR T Cells as a Targeted Therapy for Triple-Negative Breast Cancer. Cancer Res 78:489-500
Xing, Zhen; Zhang, Yanyan; Liang, Ke et al. (2018) Expression of Long Noncoding RNA YIYA Promotes Glycolysis in Breast Cancer. Cancer Res 78:4524-4532
Chiang, Angie C A; Fowler, Stephanie W; Savjani, Ricky R et al. (2018) Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med 215:1349-1364
Szwarc, Maria M; Hai, Lan; Gibbons, William E et al. (2018) Retinoid signaling controlled by SRC-2 in decidualization revealed by transcriptomics Reproduction 156:387-395
Nguyen, Tuan M; Kabotyanski, Elena B; Dou, Yongchao et al. (2018) FGFR1-Activated Translation of WNT Pathway Components with Structured 5' UTRs Is Vulnerable to Inhibition of EIF4A-Dependent Translation Initiation. Cancer Res 78:4229-4240
Kho, Jordan; Tian, Xiaoyu; Wong, Wing-Tak et al. (2018) Argininosuccinate Lyase Deficiency Causes an Endothelial-Dependent Form of Hypertension. Am J Hum Genet 103:276-287
Liu, Yanhong; O'Brien, Jacqueline L; Ajami, Nadim J et al. (2018) Lung tissue microbial profile in lung cancer is distinct from emphysema. Am J Cancer Res 8:1775-1787
Scavuzzo, Marissa A; Hill, Matthew C; Chmielowiec, Jolanta et al. (2018) Endocrine lineage biases arise in temporally distinct endocrine progenitors during pancreatic morphogenesis. Nat Commun 9:3356

Showing the most recent 10 out of 991 publications